ZyVersa Therapeutics Book Value Per Share Growth & History (ZVSA)
ZyVersa Therapeutics's book value per share was -$1.53 for fiscal 2025.
View full ZyVersa Therapeutics company overviewZyVersa Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$1.53 | -$4.93 | — |
| 2024 | 2024-12-31 | $3.40 | -$24.14 | −87.67% |
| 2023 | 2023-12-31 | $27.53 | — | — |
| 2022 · Dec 31 | 2022-12-31 | $3,868.85 | — | — |
| 2022 · Dec 12 | 2022-12-12 | $41.20 | — | — |
ZyVersa Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | -$1.74 | -$4.91 | — |
| Q4 2025 | 2025-12-31 | -$1.53 | -$4.93 | — |
| Q3 2025 | 2025-09-30 | -$1.45 | -$7.99 | — |
| Q2 2025 | 2025-06-30 | $1.25 | -$9.07 | −87.88% |
| Q1 2025 | 2025-03-31 | $3.17 | -$10.28 | −76.45% |
| Q4 2024 | 2024-12-31 | $3.40 | -$24.14 | −87.67% |
| Q3 2024 | 2024-09-30 | $6.54 | -$151.94 | −95.87% |
| Q2 2024 | 2024-06-30 | $10.32 | -$286.36 | −96.52% |
| Q1 2024 | 2024-03-31 | $13.44 | -$3,675.74 | −99.64% |
| Q4 2023 | 2023-12-31 | $27.53 | -$3,841.31 | −99.29% |
| Q3 2023 | 2023-09-30 | $158.48 | — | — |
| Q2 2023 | 2023-06-30 | $296.68 | — | — |
| Q1 2023 | 2023-03-31 | $3,689.18 | — | — |
| Q4 2022 | 2022-12-31 | $3,868.85 | — | — |
ZyVersa Therapeutics book value per share trends
Between the periods ended 2022-12-12 and 2025-12-31, ZyVersa Therapeutics's book value per share decreased from $41.20 to -$1.53, a change of -$42.73. The latest reported quarter, Q1 2026, shows -$1.74.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ZyVersa Therapeutics source filings ↗